You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTopiramate
Accession NumberDB00273  (APRD00237)
TypeSmall Molecule
GroupsApproved
DescriptionTopiramate (brand name Topamax) is an anticonvulsant drug produced by Ortho-McNeil Neurologics, a division of Johnson & Johnson. It is used to treat epilepsy in both children and adults. In children it is also indicated for treatment of Lennox-Gastaut syndrome (a disorder that causes seizures and developmental delays). It is also Food and Drug Administration (FDA) approved for, and now most frequently prescribed for, the prevention of migraines. [Wikipedia]. A combination product containing phentermine and topiramate extended-release called QSYMIA® is indicated for the management of obesity. On August 2013, an extended released formulation, marketed as Trokendi XR has been approved for the management of partial onset, tonic-clonic, and Lennox-Gastaut Syndrome seizures.
Structure
Thumb
Synonyms
2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate
McN-4853
RWJ-17021
Tipiramate
Tipiramato
Topamax
Topiramate
Topiramato
Topiramatum
TPM
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Abbott-topiramatetablet25 mgoralBgp Pharma Ulc2014-03-122015-12-31Canada
Abbott-topiramatetablet100 mgoralBgp Pharma Ulc2014-03-122015-12-31Canada
Abbott-topiramatetablet200 mgoralBgp Pharma Ulc2014-03-172015-12-31Canada
Accel-topiramatetablet25 mgoralAccel Pharma Inc2015-03-26Not applicableCanada
Accel-topiramatetablet100 mgoralAccel Pharma Inc2015-03-26Not applicableCanada
Accel-topiramatetablet200 mgoralAccel Pharma Inc2015-03-26Not applicableCanada
Act Topiramatetablet25 mgoralActavis Pharma Company2007-07-12Not applicableCanada
Act Topiramatetablet100 mgoralActavis Pharma Company2007-07-12Not applicableCanada
Act Topiramatetablet200 mgoralActavis Pharma Company2007-07-12Not applicableCanada
Auro-topiramatetablet200 mgoralAurobindo Pharma Limited (Unit Iii)2011-11-28Not applicableCanada
Auro-topiramatetablet50 mgoralAurobindo Pharma Limited (Unit Iii)Not applicableNot applicableCanada
Auro-topiramatetablet25 mgoralAurobindo Pharma Limited (Unit Iii)2011-11-28Not applicableCanada
Auro-topiramatetablet100 mgoralAurobindo Pharma Limited (Unit Iii)2011-11-28Not applicableCanada
Ava-topiramatetablet25 mgoralAvanstra Inc2011-10-112014-08-21Canada
Ava-topiramatetablet100 mgoralAvanstra Inc2011-10-112014-08-21Canada
Ava-topiramatetablet200 mgoralAvanstra Inc2011-10-112014-08-21Canada
Dom-topiramatetablet25 mgoralDominion Pharmacal2005-09-29Not applicableCanada
Dom-topiramatetablet100 mgoralDominion Pharmacal2005-09-29Not applicableCanada
Dom-topiramatetablet200 mgoralDominion Pharmacal2005-09-29Not applicableCanada
Gd-topiramatetablet25 mgoralGenmed A Division Of Pfizer Canada Inc2012-05-102014-12-10Canada
Gd-topiramatetablet100 mgoralGenmed A Division Of Pfizer Canada Inc2012-05-102014-12-10Canada
Gd-topiramatetablet200 mgoralGenmed A Division Of Pfizer Canada Inc2012-05-102015-08-25Canada
Ipg-topiramatetablet100 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-topiramatetablet200 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-topiramatetablet25 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-topiramatetablet25 mgoralJamp Pharma Corporation2015-02-06Not applicableCanada
Jamp-topiramatetablet100 mgoralJamp Pharma Corporation2015-02-06Not applicableCanada
Jamp-topiramatetablet200 mgoralJamp Pharma Corporation2015-02-06Not applicableCanada
Mar-topiramatetablet200 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-topiramatetablet25 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-topiramatetablet100 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mint-topiramatetablet100 mgoralMint Pharmaceuticals Inc2008-10-01Not applicableCanada
Mint-topiramatetablet200 mgoralMint Pharmaceuticals Inc2008-10-01Not applicableCanada
Mint-topiramatetablet25 mgoralMint Pharmaceuticals Inc2008-10-02Not applicableCanada
Mylan-topiramatetablet25 mgoralMylan Pharmaceuticals Ulc2005-09-14Not applicableCanada
Mylan-topiramatetablet100 mgoralMylan Pharmaceuticals Ulc2005-09-14Not applicableCanada
Mylan-topiramatetablet200 mgoralMylan Pharmaceuticals Ulc2005-09-14Not applicableCanada
Nu-topiramatetablet100 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-topiramatetablet200 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-topiramatetablet25 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-topiramatetablet50 mgoralNu Pharm IncNot applicableNot applicableCanada
PHL-topiramatetablet25 mgoralPharmel Inc2005-10-11Not applicableCanada
PHL-topiramatetablet100 mgoralPharmel Inc2005-10-11Not applicableCanada
PHL-topiramatetablet200 mgoralPharmel Inc2005-10-11Not applicableCanada
PMS-topiramatetablet200 mgoralPharmascience Inc2005-09-14Not applicableCanada
PMS-topiramatetablet25 mgoralPharmascience Inc2005-09-14Not applicableCanada
PMS-topiramatetablet100 mgoralPharmascience Inc2005-09-14Not applicableCanada
PMS-topiramatetablet50 mgoralPharmascience Inc2008-06-17Not applicableCanada
Pro-topiramatetablet25 mgoralPro Doc Limitee2008-10-27Not applicableCanada
Pro-topiramatetablet100 mgoralPro Doc Limitee2008-10-27Not applicableCanada
Pro-topiramatetablet200 mgoralPro Doc Limitee2008-10-27Not applicableCanada
Q-topiramatetablet25 mgoralQd Pharmaceuticals Ulc2012-02-032015-08-21Canada
Q-topiramatetablet100 mgoralQd Pharmaceuticals Ulc2012-02-032015-08-21Canada
Q-topiramatetablet200 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Qudexy XRcapsule, extended release25 mg/1oralUpsher Smith Laboratories, Inc.2014-04-11Not applicableUs
Qudexy XRcapsule, extended release150 mg/1oralUpsher Smith Laboratories, Inc.2014-04-11Not applicableUs
Qudexy XRcapsule, extended release50 mg/1oralUpsher Smith Laboratories, Inc.2014-04-11Not applicableUs
Qudexy XRcapsule, extended release200 mg/1oralUpsher Smith Laboratories, Inc.2014-04-11Not applicableUs
Qudexy XRcapsule, extended release100 mg/1oralUpsher Smith Laboratories, Inc.2014-04-11Not applicableUs
Ran-topiramatetablet25 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-03-22Not applicableCanada
Ran-topiramatetablet100 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-03-22Not applicableCanada
Ran-topiramatetablet200 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-03-22Not applicableCanada
Ratio-topiramatetablet25 mgoralTeva Canada Limited2005-09-142012-07-21Canada
Ratio-topiramatetablet100 mgoralTeva Canada Limited2005-09-142012-07-21Canada
Ratio-topiramatetablet200 mgoralTeva Canada Limited2005-09-142012-07-21Canada
Sandoz Topiramatetablet25 mgoralSandoz Canada Incorporated2005-09-14Not applicableCanada
Sandoz Topiramatetablet200 mgoralSandoz Canada Incorporated2005-09-14Not applicableCanada
Sandoz Topiramatetablet100 mgoralSandoz Canada Incorporated2005-09-14Not applicableCanada
Sandoz Topiramate Tabletstablet200 mgoralSandoz Canada Incorporated2014-10-31Not applicableCanada
Sandoz Topiramate Tabletstablet100 mgoralSandoz Canada Incorporated2014-10-31Not applicableCanada
Sandoz Topiramate Tabletstablet25 mgoralSandoz Canada Incorporated2014-10-31Not applicableCanada
Teva-topiramatetablet25 mgoralTeva Canada Limited2005-09-14Not applicableCanada
Teva-topiramatetablet100 mgoralTeva Canada Limited2005-09-14Not applicableCanada
Teva-topiramatetablet200 mgoralTeva Canada Limited2005-11-25Not applicableCanada
Topamaxcapsule, coated pellets15 mg/1oralJanssen Pharmaceuticals, Inc.1998-11-01Not applicableUs
Topamaxtablet, coated50 mg/1oralRebel Distributors Corp1997-01-01Not applicableUs
Topamaxtablet, coated50 mg/1oralPhysicians Total Care, Inc.2005-07-05Not applicableUs
Topamaxtablet, coated100 mg/1oralJanssen Pharmaceuticals, Inc.1997-01-01Not applicableUs
Topamaxtablet, coated25 mg/1oralPhysicians Total Care, Inc.2004-01-08Not applicableUs
Topamaxtablet, coated100 mg/1oralRebel Distributors Corp1997-01-01Not applicableUs
Topamaxtablet, coated50 mg/1oralPd Rx Pharmaceuticals, Inc.1997-01-01Not applicableUs
Topamaxtablet, coated200 mg/1oralJanssen Pharmaceuticals, Inc.1997-01-01Not applicableUs
Topamaxtablet, coated100 mg/1oralPhysicians Total Care, Inc.2003-07-23Not applicableUs
Topamaxtablet, coated25 mg/1oralJanssen Pharmaceuticals, Inc.1997-01-01Not applicableUs
Topamaxcapsule15 mgoralJanssen Inc1999-06-11Not applicableCanada
Topamaxtablet, coated25 mg/1oralbryant ranch prepack1997-01-01Not applicableUs
Topamaxcapsule, coated pellets25 mg/1oralJanssen Pharmaceuticals, Inc.1998-11-01Not applicableUs
Topamaxtablet, coated200 mg/1oralPhysicians Total Care, Inc.2004-11-29Not applicableUs
Topamaxcapsule25 mgoralJanssen Inc1999-06-11Not applicableCanada
Topamaxtablet, coated50 mg/1oralJanssen Pharmaceuticals, Inc.1997-01-01Not applicableUs
Topamaxtablet, coated25 mg/1oralRebel Distributors Corp1997-01-01Not applicableUs
Topamax 100mgtablet100 mgoralJanssen Inc1997-03-25Not applicableCanada
Topamax 200mgtablet200 mgoralJanssen Inc1997-03-25Not applicableCanada
Topamax 25mgtablet25 mgoralJanssen Inc1997-03-25Not applicableCanada
Topiramatetablet100 mgoralSivem Pharmaceuticals Ulc2012-07-20Not applicableCanada
Topiramatecapsule, extended release200 mg/1oralUpsher Smith Laboratories, Inc.2014-07-07Not applicableUs
Topiramatetablet200 mgoralSanis Health Inc2010-10-06Not applicableCanada
Topiramatetablet200 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Topiramatetablet200 mgoralMeliapharm Inc2010-06-112014-06-25Canada
Topiramatetablet50 mgoralSivem Pharmaceuticals UlcNot applicableNot applicableCanada
Topiramatecapsule, extended release100 mg/1oralUpsher Smith Laboratories, Inc.2014-07-07Not applicableUs
Topiramatecapsule, extended release25 mg/1oralUpsher Smith Laboratories, Inc.2014-07-07Not applicableUs
Topiramatetablet25 mgoralSanis Health Inc2010-10-06Not applicableCanada
Topiramatetablet200 mgoralSivem Pharmaceuticals UlcNot applicableNot applicableCanada
Topiramatecapsule, extended release150 mg/1oralUpsher Smith Laboratories, Inc.2014-07-07Not applicableUs
Topiramatetablet25 mgoralMeliapharm Inc2010-06-112014-06-26Canada
Topiramatetablet25 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Topiramatecapsule, extended release50 mg/1oralUpsher Smith Laboratories, Inc.2014-07-07Not applicableUs
Topiramatetablet100 mgoralSanis Health Inc2010-10-06Not applicableCanada
Topiramatetablet25 mgoralSivem Pharmaceuticals Ulc2012-07-20Not applicableCanada
Topiramatetablet100 mgoralMeliapharm Inc2010-06-112014-06-25Canada
Topiramatetablet100 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Topiramate Tabletstablet25 mgoralAccord Healthcare Inc2012-11-29Not applicableCanada
Topiramate Tabletstablet25 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Topiramate Tabletstablet100 mgoralAccord Healthcare Inc2012-12-14Not applicableCanada
Topiramate Tabletstablet100 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Topiramate Tabletstablet200 mgoralAccord Healthcare Inc2012-11-29Not applicableCanada
Topiramate Tabletstablet200 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Topiramate Tablets USPtablet25 mgoralAccord Healthcare Inc2014-11-14Not applicableCanada
Topiramate Tablets USPtablet100 mgoralAccord Healthcare Inc2014-11-14Not applicableCanada
Topiramate Tablets USPtablet200 mgoralAccord Healthcare Inc2014-11-14Not applicableCanada
Trokendi XRcapsule, extended release50 mg/1oralSupernus Pharmaceuticals, Inc.2013-08-16Not applicableUs
Trokendi XRcapsule, extended release100 mg/1oralSupernus Pharmaceuticals, Inc.2013-08-16Not applicableUs
Trokendi XRcapsule, extended release200 mg/1oralSupernus Pharmaceuticals, Inc.2013-08-16Not applicableUs
Trokendi XRcapsule, extended release25 mg/1oralSupernus Pharmaceuticals, Inc.2013-08-16Not applicableUs
Van-topiramatetablet200 mgoralVanc Pharmaceuticals IncNot applicableNot applicableCanada
Van-topiramatetablet25 mgoralVanc Pharmaceuticals IncNot applicableNot applicableCanada
Van-topiramatetablet100 mgoralVanc Pharmaceuticals IncNot applicableNot applicableCanada
Zym-topiramatetablet100 mgoralZymcan Pharmaceuticals Inc2009-06-232014-06-16Canada
Zym-topiramatetablet200 mgoralZymcan Pharmaceuticals Inc2009-06-232014-06-16Canada
Zym-topiramatetablet25 mgoralZymcan Pharmaceuticals Inc2009-06-232014-06-16Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-topiramatetablet200 mgoralApotex Inc2006-04-21Not applicableCanada
Apo-topiramatetablet50 mgoralApotex IncNot applicableNot applicableCanada
Apo-topiramatetablet25 mgoralApotex Inc2006-04-21Not applicableCanada
Apo-topiramatetablet100 mgoralApotex Inc2006-04-21Not applicableCanada
Topiramatetablet, film coated100 mg/1oralClinical Solutions Wholesale2009-03-27Not applicableUs
Topiramatetablet, coated25 mg/1oralHangzhou Minsheng Binjiang Pharmaceutical CO., Ltd2013-12-31Not applicableUs
Topiramatetablet, film coated25 mg/1oralDIRECT RX2014-01-01Not applicableUs
Topiramatetablet, film coated100 mg/1oralRanbaxy Pharmaceuticals Inc2010-01-04Not applicableUs
Topiramatetablet, film coated50 mg/1oralAurobindo Pharma Limited2009-03-27Not applicableUs
Topiramatetablet, coated25 mg/1oralUpsher Smith Laboratories, Inc.2010-11-17Not applicableUs
Topiramatetablet, film coated25 mg/1oralGlenmark Pharmaceuticals Inc., Usa2009-03-27Not applicableUs
Topiramatetablet, film coated100 mg/1oralWest ward Pharmaceutical Corp2013-12-02Not applicableUs
Topiramatetablet, film coated200 mg/1oralZydus Pharmaceuticals (USA) Inc.2009-03-27Not applicableUs
Topiramatetablet200 mg/1oralTorrent Pharmaceuticals Limited2009-03-27Not applicableUs
Topiramatetablet50 mg/1oralCamber Pharmaceuticals, Inc.2011-01-01Not applicableUs
Topiramatetablet100 mg/1oralPd Rx Pharmaceuticals, Inc.2009-03-27Not applicableUs
Topiramatetablet100 mg/1oralREMEDYREPACK INC.2011-07-19Not applicableUs
Topiramatetablet100 mg/1oralUnit Dose Services2011-01-01Not applicableUs
Topiramatetablet25 mg/1oralH.J. Harkins Company, Inc.2009-03-27Not applicableUs
Topiramatetablet200 mg/1oralREMEDYREPACK INC.2013-04-012016-04-05Us
Topiramatetablet, film coated25 mg/1oralPhysicians Total Care, Inc2009-04-13Not applicableUs
Topiramatetablet100 mg/1oralGolden State Medical Supply, Inc.2009-03-27Not applicableUs
Topiramatetablet, film coated50 mg/1oralREMEDYREPACK INC.2015-05-18Not applicableUs
Topiramatetablet, film coated25 mg/1oralProficient Rx LP2009-03-27Not applicableUs
Topiramatetablet, film coated25 mg/1oralCadila Healthcare Limited2009-03-27Not applicableUs
Topiramatetablet, film coated50 mg/1oralMylan Pharmaceuticals Inc.2012-12-12Not applicableUs
Topiramatetablet, film coated200 mg/1oralDispensing Solutions Inc.2009-04-13Not applicableUs
Topiramatetablet25 meq/1oralCipla USA Inc.2014-06-12Not applicableUs
Topiramatetablet25 mg/1oralTeva Pharmaceuticals USA Inc2009-03-31Not applicableUs
Topiramatetablet, film coated100 mg/1oralREMEDYREPACK INC.2016-03-11Not applicableUs
Topiramatetablet25 mg/1oralBlenheim Pharmacal, Inc.2014-01-22Not applicableUs
Topiramatetablet, film coated100 mg/1oralRebel Distributors Corp2009-03-27Not applicableUs
Topiramatetablet, film coated100 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-10-28Not applicableUs
Topiramatetablet, film coated50 mg/1oralSun Pharma Global FZE2014-12-15Not applicableUs
Topiramatetablet200 mg/1oralREMEDYREPACK INC.2013-02-20Not applicableUs
Topiramatetablet25 mg/1oralSTAT Rx USA LLC2009-03-27Not applicableUs
Topiramatetablet50 mg/1oralAidarex Pharmaceuticals LLC2011-01-01Not applicableUs
Topiramatetablet, film coated25 mg/1oralPd Rx Pharmaceuticals, Inc.2009-03-27Not applicableUs
Topiramatetablet100 mg/1oralREMEDYREPACK INC.2011-11-01Not applicableUs
Topiramatetablet, film coated100 mg/1oralMylan Institutional Inc.2009-04-20Not applicableUs
Topiramatetablet25 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Topiramatetablet, film coated100 mg/1oralHikma Pharmaceutical2013-12-02Not applicableUs
Topiramatetablet50 mg/1oralSt Marys Medical Park Pharmacy2010-12-29Not applicableUs
Topiramatetablet, film coated100 mg/1oralSun Pharmaceutical Industries Limited2009-03-27Not applicableUs
Topiramatetablet50 mg/1oralbryant ranch prepack2009-03-27Not applicableUs
Topiramatetablet, film coated100 mg/1oralAmerican Health Packaging2012-06-01Not applicableUs
Topiramatetablet, film coated25 mg/1oralMajor Pharmaceuticals2009-06-10Not applicableUs
Topiramatetablet, film coated25 mg/1oralPreferred Pharmaceuticals, Inc.2014-03-14Not applicableUs
Topiramatetablet, film coated100 mg/1oralCitron Pharma LLC2009-03-27Not applicableUs
Topiramatetablet, coated50 mg/1oralUpsher Smith Laboratories, Inc.2011-05-02Not applicableUs
Topiramatetablet, film coated100 mg/1oralPreferred Pharmaceuticals Inc.2016-01-11Not applicableUs
Topiramatecapsule, coated pellets25 mg/1oralTeva Pharmaceuticals USA Inc2009-04-17Not applicableUs
Topiramatetablet, film coated25 mg/1oralZydus Pharmaceuticals (USA) Inc.2009-03-27Not applicableUs
Topiramatetablet25 mg/1oralTorrent Pharmaceuticals Limited2009-03-27Not applicableUs
Topiramatetablet, film coated100 mg/1oralUnichem Pharmaceuticals (USA), Inc.2013-07-01Not applicableUs
Topiramatetablet, film coated100 mg/1oralSTAT Rx USA LLC2009-03-27Not applicableUs
Topiramatetablet25 mg/1oralREMEDYREPACK INC.2013-04-10Not applicableUs
Topiramatetablet200 mg/1oralAv Pak2014-09-17Not applicableUs
Topiramatetablet, film coated50 mg/1oralREMEDYREPACK INC.2014-02-26Not applicableUs
Topiramatetablet, film coated50 mg/1oralLake Erie Medical DBA Quality Care Products LLC2009-03-27Not applicableUs
Topiramatetablet, film coated100 mg/1oralApotex Corp2009-03-27Not applicableUs
Topiramatetablet100 mg/1oralDIRECT RX2015-01-01Not applicableUs
Topiramatetablet, film coated100 mg/1oralProficient Rx LP2009-03-27Not applicableUs
Topiramatecapsule, coated pellets15 mg/1oralCadila Healthcare Limited2009-10-14Not applicableUs
Topiramatetablet, film coated50 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-03-27Not applicableUs
Topiramatetablet25 mg/1oralKeltman Pharmaceuticals Inc.2010-07-30Not applicableUs
Topiramatetablet, film coated200 mg/1oralUnit Dose Services2009-03-27Not applicableUs
Topiramatetablet, film coated100 mg/1oralH.J. Harkins Company, Inc.2009-03-27Not applicableUs
Topiramatetablet, film coated200 mg/1oralClinical Solutions Wholesale2009-03-27Not applicableUs
Topiramatetablet, coated50 mg/1oralHangzhou Minsheng Binjiang Pharmaceutical CO., Ltd2013-12-31Not applicableUs
Topiramatetablet50 mg/1oralDIRECT RX2014-01-01Not applicableUs
Topiramatetablet, film coated200 mg/1oralRanbaxy Pharmaceuticals Inc2010-01-04Not applicableUs
Topiramatetablet, film coated100 mg/1oralAurobindo Pharma Limited2009-03-27Not applicableUs
Topiramatetablet, coated50 mg/1oralUpsher Smith Laboratories, Inc.2010-11-17Not applicableUs
Topiramatetablet, film coated100 mg/1oralGlenmark Pharmaceuticals Inc., Usa2009-03-27Not applicableUs
Topiramatetablet, film coated50 mg/1oralWest ward Pharmaceutical Corp2013-12-02Not applicableUs
Topiramatetablet25 mg/1oralPreferred Pharmaceuticals Inc.2016-01-04Not applicableUs
Topiramatecapsule, coated pellets15 mg/1oralCobalt Laboratories2009-04-15Not applicableUs
Topiramatetablet100 mg/1oralCamber Pharmaceuticals, Inc.2011-01-01Not applicableUs
Topiramatetablet, film coated25 mg/1oralPd Rx Pharmaceuticals, Inc.2009-03-27Not applicableUs
Topiramatetablet50 mg/1oralREMEDYREPACK INC.2011-07-20Not applicableUs
Topiramatetablet, film coated100 mg/1oralSun Pharma Global FZE2014-12-15Not applicableUs
Topiramatetablet25 mg/1oralAv Pak2014-09-17Not applicableUs
Topiramatetablet, film coated25 mg/1oralREMEDYREPACK INC.2013-02-26Not applicableUs
Topiramatetablet, film coated50 mg/1oralPhysicians Total Care, Inc2009-05-06Not applicableUs
Topiramatetablet200 mg/1oralGolden State Medical Supply, Inc.2009-03-27Not applicableUs
Topiramatetablet50 mg/1oralDIRECT RX2014-01-01Not applicableUs
Topiramatetablet, film coated25 mg/1oralProficient Rx LP2009-03-27Not applicableUs
Topiramatetablet, film coated50 mg/1oralCadila Healthcare Limited2009-03-27Not applicableUs
Topiramatetablet, film coated100 mg/1oralMylan Pharmaceuticals Inc.2012-12-12Not applicableUs
Topiramatetablet, film coated100 mg/1oralDispensing Solutions Inc.2009-04-13Not applicableUs
Topiramatetablet50 mg/1oralCipla USA Inc.2014-06-12Not applicableUs
Topiramatetablet100 mg/1oralTeva Pharmaceuticals USA Inc2009-03-31Not applicableUs
Topiramatetablet, film coated50 mg/1oralPreferred Pharmaceuticalc Inc.2009-03-27Not applicableUs
Topiramatetablet, film coated50 mg/1oralBlenheim Pharmacal, Inc.2013-10-08Not applicableUs
Topiramatetablet, film coated200 mg/1oralRebel Distributors Corp2009-03-27Not applicableUs
Topiramatetablet, film coated200 mg/1oralLake Erie Medical DBA Quality Care Products LLC2009-03-27Not applicableUs
Topiramatetablet, film coated100 mg/1oralPreferred Pharmacetucals, Inc.2013-12-18Not applicableUs
Topiramatetablet, film coated200 mg/1oralCitron Pharma LLC2009-03-27Not applicableUs
Topiramatetablet, coated100 mg/1oralUpsher Smith Laboratories, Inc.2011-05-02Not applicableUs
Topiramatetablet50 mg/1oralSTAT Rx USA LLC2009-03-27Not applicableUs
Topiramatetablet100 mg/1oralAidarex Pharmaceuticals LLC2011-01-01Not applicableUs
Topiramatetablet, film coated100 mg/1oralPd Rx Pharmaceuticals, Inc.2009-03-27Not applicableUs
Topiramatetablet200 mg/1oralREMEDYREPACK INC.2011-11-17Not applicableUs
Topiramatetablet, film coated25 mg/1oralNorthwind Pharmaceuticals, LLC2015-02-10Not applicableUs
Topiramatetablet, film coated25 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Topiramatetablet, film coated200 mg/1oralHikma Pharmaceutical2013-12-02Not applicableUs
Topiramatetablet100 mg/1oralSt Marys Medical Park Pharmacy2010-12-24Not applicableUs
Topiramatetablet, film coated200 mg/1oralSun Pharmaceutical Industries Limited2009-03-27Not applicableUs
Topiramatetablet, film coated200 mg/1oralbryant ranch prepack2009-03-27Not applicableUs
Topiramatetablet, film coated200 mg/1oralAmerican Health Packaging2012-06-01Not applicableUs
Topiramatetablet, film coated50 mg/1oralMajor Pharmaceuticals2009-06-10Not applicableUs
Topiramatecapsule, coated pellets25 mg/1oralCadila Healthcare Limited2009-10-14Not applicableUs
Topiramatetablet, film coated100 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-03-27Not applicableUs
Topiramatetablet100 mg/1oralKeltman Pharmaceuticals Inc.2010-07-30Not applicableUs
Topiramatetablet50 mg/1oralTeva Pharmaceuticals USA Inc2009-03-31Not applicableUs
Topiramatetablet, film coated50 mg/1oralZydus Pharmaceuticals (USA) Inc.2009-03-27Not applicableUs
Topiramatetablet50 mg/1oralTorrent Pharmaceuticals Limited2009-03-27Not applicableUs
Topiramatetablet, film coated200 mg/1oralUnichem Pharmaceuticals (USA), Inc.2013-07-01Not applicableUs
Topiramatetablet25 mg/1oralPd Rx Pharmaceuticals, Inc.2009-03-27Not applicableUs
Topiramatetablet50 mg/1oralREMEDYREPACK INC.2011-04-25Not applicableUs
Topiramatetablet25 mg/1oralUnit Dose Services2011-01-01Not applicableUs
Topiramatetablet, film coated25 mg/1oralREMEDYREPACK INC.2014-03-12Not applicableUs
Topiramatetablet, film coated200 mg/1oralClinical Solutions Wholesale2009-03-27Not applicableUs
Topiramatetablet, film coated200 mg/1oralApotex Corp2009-03-27Not applicableUs
Topiramatetablet, film coated100 mg/1oralDIRECT RX2014-01-01Not applicableUs
Topiramatetablet, film coated50 mg/1oralProficient Rx LP2009-03-27Not applicableUs
Topiramatetablet, film coated100 mg/1oralPd Rx Pharmaceuticals, Inc.2009-03-27Not applicableUs
Topiramatetablet100 mg/1oralREMEDYREPACK INC.2011-09-13Not applicableUs
Topiramatetablet, film coated25 mg/1oralMylan Institutional Inc.2009-04-20Not applicableUs
Topiramatetablet50 mg/1oralH.J. Harkins Company, Inc.2009-03-27Not applicableUs
Topiramatetablet, film coated25 mg/1oralHikma Pharmaceutical2013-12-02Not applicableUs
Topiramatetablet, coated100 mg/1oralHangzhou Minsheng Binjiang Pharmaceutical CO., Ltd2013-12-31Not applicableUs
Topiramatetablet, film coated25 mg/1oralSun Pharmaceutical Industries Limited2009-03-27Not applicableUs
Topiramatetablet, film coated100 mg/1oralbryant ranch prepack2009-03-27Not applicableUs
Topiramatetablet, film coated200 mg/1oralAurobindo Pharma Limited2009-03-27Not applicableUs
Topiramatetablet, coated100 mg/1oralUpsher Smith Laboratories, Inc.2010-11-17Not applicableUs
Topiramatetablet, film coated200 mg/1oralGlenmark Pharmaceuticals Inc., Usa2009-03-27Not applicableUs
Topiramatetablet, film coated25 mg/1oralCitron Pharma LLC2009-03-27Not applicableUs
Topiramatetablet, film coated25 mg/1oralWest ward Pharmaceutical Corp2013-12-02Not applicableUs
Topiramatetablet, film coated50 mg/1oralPreferred Pharmaceuticals Inc.2016-04-14Not applicableUs
Topiramatecapsule, coated pellets25 mg/1oralCobalt Laboratories2009-04-15Not applicableUs
Topiramatetablet200 mg/1oralCamber Pharmaceuticals, Inc.2011-01-01Not applicableUs
Topiramatetablet, film coated25 mg/1oralUnichem Pharmaceuticals (USA), Inc.2013-07-01Not applicableUs
Topiramatetablet, film coated25 mg/1oralSTAT Rx USA LLC2009-03-27Not applicableUs
Topiramatetablet, film coated200 mg/1oralSun Pharma Global FZE2014-12-15Not applicableUs
Topiramatetablet50 mg/1oralAv Pak2014-09-17Not applicableUs
Topiramatetablet, film coated100 mg/1oralREMEDYREPACK INC.2013-03-08Not applicableUs
Topiramatetablet, film coated100 mg/1oralCardinal Health2012-01-05Not applicableUs
Topiramatetablet, film coated25 mg/1oralApotex Corp2009-03-27Not applicableUs
Topiramatetablet100 mg/1oralDIRECT RX2015-01-01Not applicableUs
Topiramatetablet50 mg/1oralProficient Rx LP2011-01-01Not applicableUs
Topiramatetablet, film coated100 mg/1oralCadila Healthcare Limited2009-03-27Not applicableUs
Topiramatetablet, film coated200 mg/1oralMylan Pharmaceuticals Inc.2012-12-12Not applicableUs
Topiramatetablet, film coated100 mg/1oralDispensing Solutions, Inc.2009-03-27Not applicableUs
Topiramatetablet100 mg/1oralCipla USA Inc.2014-06-12Not applicableUs
Topiramatetablet200 mg/1oralTeva Pharmaceuticals USA Inc2009-03-312016-02-29Us
Topiramatecapsule, coated pellets15 mg/1oralZydus Pharmaceuticals (USA) Inc.2009-10-14Not applicableUs
Topiramatetablet25 mg/1oralApotheca, Inc2010-05-13Not applicableUs
Topiramatetablet, film coated25 mg/1oralDispensing Solutions Inc.2009-04-13Not applicableUs
Topiramatetablet, film coated100 mg/1oralMajor Pharmaceuticals2009-06-10Not applicableUs
Topiramatetablet, film coated50 mg/1oralPreferred Pharmacetucals, Inc.2013-12-18Not applicableUs
Topiramatetablet, film coated25 mg/1oralREMEDYREPACK INC.2016-02-09Not applicableUs
Topiramatetablet, coated200 mg/1oralUpsher Smith Laboratories, Inc.2011-05-02Not applicableUs
Topiramatetablet, film coated25 mg/1oralRebel Distributors Corp2009-03-27Not applicableUs
Topiramatetablet, film coated25 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-29Not applicableUs
Topiramatetablet, film coated50 mg/1oralPd Rx Pharmaceuticals, Inc.2009-03-27Not applicableUs
Topiramatetablet50 mg/1oralREMEDYREPACK INC.2012-03-12Not applicableUs
Topiramatetablet, film coated100 mg/1oralNorthwind Pharmaceuticals, LLC2015-02-02Not applicableUs
Topiramatetablet, film coated100 mg/1oralPhysicians Total Care, Inc2009-05-08Not applicableUs
Topiramatetablet25 mg/1oralGolden State Medical Supply, Inc.2009-03-27Not applicableUs
Topiramatetablet25 mg/1oralSt Marys Medical Park Pharmacy2010-12-29Not applicableUs
Topiramatetablet, film coated50 mg/1oralProficient Rx LP2009-03-27Not applicableUs
Topiramatetablet, film coated25 mg/1oralTYA Pharmaceuticals2009-03-27Not applicableUs
Topiramatetablet, film coated25 mg/1oralRanbaxy Pharmaceuticals Inc2010-01-04Not applicableUs
Topiramatetablet, film coated25 mg/1oralAurobindo Pharma Limited2009-03-27Not applicableUs
Topiramatetablet, film coated200 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-03-27Not applicableUs
Topiramatetablet200 mg/1oralKeltman Pharmaceuticals Inc.2010-07-30Not applicableUs
Topiramatetablet, film coated200 mg/1oralWest ward Pharmaceutical Corp2013-12-02Not applicableUs
Topiramatetablet, film coated100 mg/1oralZydus Pharmaceuticals (USA) Inc.2009-03-27Not applicableUs
Topiramatetablet100 mg/1oralTorrent Pharmaceuticals Limited2009-03-27Not applicableUs
Topiramatetablet25 mg/1oralCamber Pharmaceuticals, Inc.2011-01-01Not applicableUs
Topiramatetablet, film coated50 mg/1oralPd Rx Pharmaceuticals, Inc.2009-03-27Not applicableUs
Topiramatetablet25 mg/1oralREMEDYREPACK INC.2011-08-22Not applicableUs
Topiramatetablet50 mg/1oralUnit Dose Services2011-01-01Not applicableUs
Topiramatetablet, film coated100 mg/1oralREMEDYREPACK INC.2014-04-21Not applicableUs
Topiramatetablet, film coated50 mg/1oralClinical Solutions Wholesale2009-03-27Not applicableUs
Topiramatecapsule, coated pellets25 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Topiramatetablet, film coated200 mg/1oralDIRECT RX2015-01-01Not applicableUs
Topiramatetablet100 mg/1oralSTAT Rx USA LLC2009-03-27Not applicableUs
Topiramatetablet, film coated25 mg/1oralAidarex Pharmaceuticals LLC2009-03-27Not applicableUs
Topiramatetablet50 mg/1oralPd Rx Pharmaceuticals, Inc.2009-03-27Not applicableUs
Topiramatetablet25 mg/1oralREMEDYREPACK INC.2011-09-07Not applicableUs
Topiramatetablet, film coated50 mg/1oralMylan Institutional Inc.2009-04-20Not applicableUs
Topiramatetablet, film coated25 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Topiramatetablet, film coated50 mg/1oralHikma Pharmaceutical2013-12-02Not applicableUs
Topiramatetablet25 mg/1oralSt Marys Medical Park Pharmacy2009-03-27Not applicableUs
Topiramatetablet, film coated50 mg/1oralSun Pharmaceutical Industries Limited2009-03-27Not applicableUs
Topiramatetablet25 mg/1oralbryant ranch prepack2009-03-27Not applicableUs
Topiramatetablet, film coated25 mg/1oralAmerican Health Packaging2012-06-01Not applicableUs
Topiramatetablet, coated200 mg/1oralUpsher Smith Laboratories, Inc.2010-11-17Not applicableUs
Topiramatetablet, film coated50 mg/1oralGlenmark Pharmaceuticals Inc., Usa2009-03-27Not applicableUs
Topiramatetablet, film coated50 mg/1oralCitron Pharma LLC2009-03-27Not applicableUs
Topiramatetablet, coated25 mg/1oralUpsher Smith Laboratories, Inc.2011-05-02Not applicableUs
Topiramatetablet50 mg/1oralApotheca, Inc2010-05-13Not applicableUs
Topiramatetablet, film coated50 mg/1oralUnichem Pharmaceuticals (USA), Inc.2013-07-01Not applicableUs
Topiramatetablet, film coated50 mg/1oralSTAT Rx USA LLC2009-03-27Not applicableUs
Topiramatetablet100 mg/1oralREMEDYREPACK INC.2013-04-102016-04-05Us
Topiramatetablet100 mg/1oralAv Pak2014-09-17Not applicableUs
Topiramatetablet25 mg/1oralREMEDYREPACK INC.2013-05-222016-04-05Us
Topiramatetablet, film coated25 mg/1oralCardinal Health2012-01-05Not applicableUs
Topiramatetablet, film coated50 mg/1oralApotex Corp2009-03-27Not applicableUs
Topiramatetablet25 mg/1oralDIRECT RX2015-01-01Not applicableUs
Topiramatetablet, film coated25 mg/1oralProficient Rx LP2009-03-272016-02-05Us
Topiramatetablet, film coated200 mg/1oralCadila Healthcare Limited2009-03-27Not applicableUs
Topiramatetablet, film coated25 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-03-27Not applicableUs
Topiramatetablet, film coated200 mg/1oralDispensing Solutions, Inc.2009-03-27Not applicableUs
Topiramatetablet200 1/1oralCipla USA Inc.2014-06-12Not applicableUs
Topiramatecapsule, coated pellets15 mg/1oralTeva Pharmaceuticals USA Inc2009-04-17Not applicableUs
Topiramatecapsule, coated pellets25 mg/1oralZydus Pharmaceuticals (USA) Inc.2009-10-14Not applicableUs
Topiramatetablet, film coated100 mg/1oralProficient Rx LP2009-03-27Not applicableUs
Topiramatetablet, film coated50 mg/1oralTYA Pharmaceuticals2009-03-27Not applicableUs
Topiramatetablet, film coated50 mg/1oralDispensing Solutions Inc.2009-04-13Not applicableUs
Topiramatetablet, film coated100 mg/1oralBlenheim Pharmacal, Inc.2013-10-08Not applicableUs
Topiramatetablet25 mg/1oralPreferred Pharmaceuticals, Inc.2012-10-31Not applicableUs
Topiramatetablet, film coated200 mg/1oralREMEDYREPACK INC.2016-03-01Not applicableUs
Topiramatetablet, film coated25 mg/1oralMylan Pharmaceuticals Inc.2012-12-12Not applicableUs
Topiramatetablet, film coated50 mg/1oralRebel Distributors Corp2009-03-27Not applicableUs
Topiramatetablet, film coated50 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-29Not applicableUs
Topiramatetablet, film coated25 mg/1oralSun Pharma Global FZE2014-12-15Not applicableUs
Topiramatetablet200 mg/1oralREMEDYREPACK INC.2012-03-29Not applicableUs
Topiramatetablet, film coated50 mg/1oralNorthwind Pharmaceuticals, LLC2014-11-06Not applicableUs
Topiramatetablet, film coated200 mg/1oralPhysicians Total Care, Inc2010-03-22Not applicableUs
Topiramatetablet50 mg/1oralGolden State Medical Supply, Inc.2009-03-27Not applicableUs
Topiramatetablet, film coated100 mg/1oralREMEDYREPACK INC.2015-05-18Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
QsymiaVIVUS, Inc.
SaltsNot Available
Categories
UNII0H73WJJ391
CAS number97240-79-4
WeightAverage: 339.362
Monoisotopic: 339.098787343
Chemical FormulaC12H21NO8S
InChI KeyInChIKey=KJADKKWYZYXHBB-XBWDGYHZSA-N
InChI
InChI=1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)/t7-,8-,9+,12+/m1/s1
IUPAC Name
[(1R,2S,6S,9R)-4,4,11,11-tetramethyl-3,5,7,10,12-pentaoxatricyclo[7.3.0.0²,⁶]dodecan-6-yl]methyl sulfamate
SMILES
[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dioxolopyrans. These are compounds containing a dioxolopyran moiety, which consistts of a dioxole ring fused to a pyran ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDioxolopyrans
Sub ClassNot Available
Direct ParentDioxolopyrans
Alternative Parents
Substituents
  • Dioxolopyran
  • Oxane
  • Monosaccharide
  • Organic sulfuric acid or derivatives
  • Meta-dioxolane
  • Oxacycle
  • Acetal
  • Hydrocarbon derivative
  • Organooxygen compound
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationUsed for the treatment and control of partial seizures and severe tonic-clonic (grand mal) seizures and also for the prevention of migraine headaches. In children it is also used for treatment of Lennox-Gastaut syndrome. Qsymia® is indicated for the treatment and management of obesity.
PharmacodynamicsTopiramate is an anticonvulsant indicated in the treatment of epilepsy and migraine. Topiramate enhances GABA-activated chloride channels. In addition, topiramate inhibits excitatory neurotransmission, through actions on kainate and AMPA receptors. There is evidence that topiramate has a specific effect on GluR5 kainate receptors. It is also an inhibitor of carbonic anhydrase, particular subtypes II and IV, but this action is weak and unlikely to be related to its anticonvulsant actions, but may account for the bad taste and the development of renal stones seen during treatment. Its possible effect as a mood stabilizer seems to occur before anticonvulsant qualities at lower dosages. Topiramate inhibits maximal electroshock and pentylenetetrazol-induced seizures as well as partial and secundarily generalized tonic-clonic seizures in the kindling model, findings predective of a broad spectrum of antiseizure activities clinically.
Mechanism of actionThe precise mechanism of action of topiramate is not known. However, studies have shown that topiramate blocks the action potentials elicited repetitively by a sustained depolarization of the neurons in a time-dependent manner, suggesting a state-dependent sodium channel blocking action. Topiramate also augments the activity of the neurotransmitter gamma-aminobutyrate (GABA) at some subtypes of the GABAA receptor (controls an integral chloride channel), indicating a possible mechanism through potentiation of the activity of GABA. Topiramate also demonstrates antagonism of the AMPA/kainate subtype of the glutamate excitatory amino acid receptor. It also inhibits carbonic anhydrase (particularly isozymes II and IV), but this action is weak and unlikely to be related to its anticonvulsant actions.
Related Articles
AbsorptionRapid with pleak plasma concentrations occurring after 2 hours and a bioavailability of 80%. The pharmacokinetic profile of the extended release formulation is non linear at 25 mg due to binding of topiramate to carbonic anhydrase in red blood cells. The peak plasma concentration was 24 hours after a single 200 mg oral dose of the extended release formulation. It is also bioequivalent to immediate-release tablet that has been administered twice-daily. Fluctuation of topiramate plasma concentrations at steady-state for Trokendi XR™ administered once-daily was approximately 26% and 42% in healthy subjects and in epileptic patients, respectively, compared to approximately 40% and 51%, respectively, for immediate-release topiramate. When topiramate is given to elderly and young adults, the maximum plasma concentration was achieved in 1 to 2 hours.
Volume of distributionNot Available
Protein binding15-41% (over the blood concentration range of 0.5 - 250 mg/mL). The fraction bound decreased as blood concentration increased. Carbamazepine and phenytoin do not alter the binding of immediate-release topiramate. Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of immediate-release topiramate from 23% to 13%. Immediate-release topiramate does not influence the binding of sodium valproate.
Metabolism

Not extensively metabolized, 70% of the dose is eliminated unchanged in the urine. The other 30% is metabolized hepatically to six metabolites (formed by hydroxylation, hydrolysis, and glucuronidation), none of which constitute more than 5% of an administered dose. There is evidence of renal tubular reabsorption of topiramate.

Route of eliminationTopiramate is not extensively metabolized and is primarily eliminated unchanged in the urine (approximately 70% of an administered dose).
Half life19 to 23 hours. The mean elimination half-life was 31 hours following repeat administration of the extended-release formulation.
Clearance
  • Plasma clearance (CL/F) =20-30 mL/min [in humans following oral administration]
    Clearance in adults was not affected by gender or race. Pediatric patients on adjunctive treatment exhibited a higher oral clearance compared to those on monotherapy. This may be because of concomitant administration with enzyme-inducing antiepileptic drugs.
ToxicitySymptoms of overdose include abdominal pain, agitation, blurred vision, convulsions, depression, dizziness, double vision, drowsiness, impaired coordination, impaired mental activity, low blood pressure, reduced consciousness, severe diarrhea, sluggishness, and speech problems.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9955
Blood Brain Barrier+0.9382
Caco-2 permeable-0.6055
P-glycoprotein substrateNon-substrate0.7905
P-glycoprotein inhibitor INon-inhibitor0.5311
P-glycoprotein inhibitor IINon-inhibitor0.9479
Renal organic cation transporterNon-inhibitor0.9131
CYP450 2C9 substrateNon-substrate0.9479
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.542
CYP450 1A2 substrateNon-inhibitor0.6623
CYP450 2C9 inhibitorNon-inhibitor0.7259
CYP450 2D6 inhibitorNon-inhibitor0.8674
CYP450 2C19 inhibitorNon-inhibitor0.6539
CYP450 3A4 inhibitorNon-inhibitor0.8469
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7952
Ames testAMES toxic0.518
CarcinogenicityNon-carcinogens0.5578
BiodegradationNot ready biodegradable0.9803
Rat acute toxicity2.5682 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8882
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Ortho mcneil janssen pharmaceuticals inc
  • Barr laboratories inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Zydus pharmaceuticals usa inc
  • Accord healthcare inc
  • Apotex inc etobicoke site
  • Aurobindo pharma ltd
  • Cipla ltd
  • Glenmark generics ltd
  • Invagen pharmaceuticals inc
  • Pliva hrvatska doo
  • Ranbaxy laboratories ltd
  • Roxane laboratories inc
  • Sun pharmaceutical industries ltd
  • Torrent pharmaceuticals ltd
  • Unichem laboratories ltd
  • Upsher smith laboratories inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral50 mg
Capsule, extended releaseoral
Capsule, extended releaseoral100 mg/1
Capsule, extended releaseoral150 mg/1
Capsule, extended releaseoral200 mg/1
Capsule, extended releaseoral25 mg/1
Capsule, extended releaseoral50 mg/1
Capsuleoral15 mg
Capsuleoral25 mg
Tabletoral100 mg
Tabletoral200 mg
Tabletoral25 mg
Capsule, coated pelletsoral15 mg/1
Capsule, coated pelletsoral25 mg/1
Tabletoral100 mg/1
Tabletoral200 1/1
Tabletoral200 mg/1
Tabletoral25 mg/1
Tabletoral25 meq/1
Tabletoral50 mg/1
Tablet, coatedoral100 mg/1
Tablet, coatedoral200 mg/1
Tablet, coatedoral25 mg/1
Tablet, coatedoral50 mg/1
Tablet, film coatedoral100 mg/1
Tablet, film coatedoral200 mg/1
Tablet, film coatedoral25 mg/1
Tablet, film coatedoral50 mg/1
Prices
Unit descriptionCostUnit
Topiramate 200 mg tablet8.32USD tablet
Topamax 200 mg tablet7.68USD tablet
Topiramate 100 mg tablet7.11USD tablet
Topamax 100 mg tablet6.31USD tablet
Topamax 50 mg tablet5.96USD tablet
Topiramate 50 mg tablet5.21USD tablet
Topiramate 25 mg Sprinkle Capsule3.04USD capsule
Topiramate 25 mg tablet2.61USD tablet
Topiramate 99.7% powder2.59USD g
Topiramate 15 mg Sprinkle Capsule2.52USD capsule
Topamax 25 mg tablet2.46USD tablet
Co Topiramate 200 mg Tablet2.08USD tablet
Mylan-Topiramate 200 mg Tablet2.08USD tablet
Novo-Topiramate 200 mg Tablet2.08USD tablet
Phl-Topiramate 200 mg Tablet2.08USD tablet
Pms-Topiramate 200 mg Tablet2.08USD tablet
Ratio-Topiramate 200 mg Tablet2.08USD tablet
Sandoz Topiramate 200 mg Tablet2.08USD tablet
Topamax Sprinkle 25 mg Capsule1.35USD capsule
Sandoz Topiramate 100 mg Tablet1.31USD tablet
Co Topiramate 100 mg Tablet1.31USD tablet
Mylan-Topiramate 100 mg Tablet1.31USD tablet
Novo-Topiramate 100 mg Tablet1.31USD tablet
Phl-Topiramate 100 mg Tablet1.31USD tablet
Pms-Topiramate 100 mg Tablet1.31USD tablet
Ratio-Topiramate 100 mg Tablet1.31USD tablet
Topamax Sprinkle 15 mg Capsule1.29USD capsule
Pms-Topiramate 50 mg Tablet1.05USD tablet
Co Topiramate 25 mg Tablet0.69USD tablet
Mylan-Topiramate 25 mg Tablet0.69USD tablet
Novo-Topiramate 25 mg Tablet0.69USD tablet
Phl-Topiramate 25 mg Tablet0.69USD tablet
Pms-Topiramate 25 mg Tablet0.69USD tablet
Ratio-Topiramate 25 mg Tablet0.69USD tablet
Sandoz Topiramate 25 mg Tablet0.69USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2322644 No2005-07-262019-03-01Canada
US5998380 Yes1996-04-132016-04-13Us
US6071537 No1997-06-232017-06-23Us
US6503884 Yes1996-04-132016-04-13Us
US7018983 Yes1996-04-132016-04-13Us
US7056890 No2000-06-142020-06-14Us
US7125560 Yes1999-09-012019-09-01Us
US7498311 Yes1996-04-132016-04-13Us
US7553818 No2000-06-142020-06-14Us
US7659256 No2000-06-142020-06-14Us
US7674776 No2000-06-142020-06-14Us
US8298576 No2008-04-042028-04-04Us
US8298580 No2007-11-162027-11-16Us
US8580298 No2009-05-152029-05-15Us
US8580299 No2009-06-142029-06-14Us
US8652527 No2013-03-192033-03-19Us
US8663683 No2007-11-162027-11-16Us
US8877248 No2007-11-162027-11-16Us
US8889190 No2013-03-192033-03-19Us
US8889191 No2007-11-162027-11-16Us
US8895057 No2008-06-092028-06-09Us
US8895058 No2008-06-092028-06-09Us
US8992989 No2007-11-162027-11-16Us
US9011905 No2008-06-092028-06-09Us
US9011906 No2008-06-092028-06-09Us
US9101545 No2013-03-192033-03-19Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility9.8 mg/mLNot Available
logP-0.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility6.8 mg/mLALOGPS
logP1.29ALOGPS
logP0.13ChemAxon
logS-1.7ALOGPS
pKa (Strongest Acidic)11.09ChemAxon
pKa (Strongest Basic)-3.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area115.54 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity72.3 m3·mol-1ChemAxon
Polarizability32.42 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Orn Almarsson, “Topiramate salts and compositions comprising and methods of making and using the same.” U.S. Patent US20040053853, issued March 18, 2004.

US20040053853
General References
  1. Blum D, Meador K, Biton V, Fakhoury T, Shneker B, Chung S, Mills K, Hammer A, Isojarvi J: Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. Neurology. 2006 Aug 8;67(3):400-6. [PubMed:16894098 ]
External Links
ATC CodesN03AX11
AHFS Codes
  • 28:12.92
PDB EntriesNot Available
FDA labelDownload (236 KB)
MSDSDownload (57.1 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Topiramate.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Topiramate.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Topiramate.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Topiramate.
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Topiramate.
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Topiramate.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Topiramate.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Topiramate.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Topiramate.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Topiramate.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Topiramate.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Topiramate.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Topiramate.
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Topiramate.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Topiramate.
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Topiramate.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Topiramate.
AmitriptylineTopiramate may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Topiramate.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Topiramate.
AmoxapineThe risk or severity of adverse effects can be increased when Topiramate is combined with Amoxapine.
AmoxicillinThe metabolism of Amoxicillin can be decreased when combined with Topiramate.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Topiramate.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Topiramate.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Topiramate.
ApixabanThe metabolism of Apixaban can be decreased when combined with Topiramate.
AprepitantThe metabolism of Aprepitant can be decreased when combined with Topiramate.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Topiramate.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Topiramate.
ArtemetherThe metabolism of Artemether can be decreased when combined with Topiramate.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Topiramate.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Topiramate.
AtomoxetineThe metabolism of Atomoxetine can be decreased when combined with Topiramate.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Topiramate.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Topiramate.
AxitinibThe metabolism of Axitinib can be decreased when combined with Topiramate.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Topiramate.
AzelastineTopiramate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Topiramate.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Topiramate.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Topiramate.
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Topiramate.
BendroflumethiazideBendroflumethiazide may increase the hypokalemic activities of Topiramate.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Topiramate.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Topiramate.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Topiramate.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Topiramate.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Topiramate.
BortezomibThe metabolism of Bortezomib can be decreased when combined with Topiramate.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Topiramate is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Topiramate.
BrimonidineThe risk or severity of adverse effects can be increased when Topiramate is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Topiramate.
BrompheniramineThe risk or severity of adverse effects can be increased when Topiramate is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Topiramate.
BumetanideBumetanide may increase the hypokalemic activities of Topiramate.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Topiramate.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Topiramate.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Topiramate.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Topiramate.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Topiramate.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Topiramate.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Topiramate.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Topiramate.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Topiramate.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Topiramate.
CarbinoxamineThe risk or severity of adverse effects can be increased when Topiramate is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Topiramate.
CarisoprodolThe risk or severity of adverse effects can be increased when Topiramate is combined with Carisoprodol.
CetirizineThe risk or severity of adverse effects can be increased when Topiramate is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Topiramate.
ChloramphenicolThe metabolism of Chloramphenicol can be decreased when combined with Topiramate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Topiramate.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Topiramate.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Topiramate.
ChlorothiazideChlorothiazide may increase the hypokalemic activities of Topiramate.
ChlorphenamineThe risk or severity of adverse effects can be increased when Topiramate is combined with Chlorphenamine.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Topiramate.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Topiramate.
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Topiramate.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Topiramate.
ChlorthalidoneChlorthalidone may increase the hypokalemic activities of Topiramate.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Topiramate is combined with Chlorzoxazone.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Topiramate.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Topiramate.
CisaprideThe metabolism of Cisapride can be decreased when combined with Topiramate.
CitalopramThe risk or severity of adverse effects can be increased when Topiramate is combined with Citalopram.
ClarithromycinThe metabolism of Clarithromycin can be decreased when combined with Topiramate.
ClemastineThe risk or severity of adverse effects can be increased when Topiramate is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Topiramate is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Topiramate is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Topiramate.
ClomipramineThe risk or severity of adverse effects can be increased when Topiramate is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Topiramate is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Topiramate is combined with Clonidine.
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Topiramate.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Topiramate.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Topiramate.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Topiramate.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Topiramate.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Topiramate.
CyclizineThe risk or severity of adverse effects can be increased when Topiramate is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Topiramate.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Topiramate.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Topiramate.
CyproheptadineThe risk or severity of adverse effects can be increased when Topiramate is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Topiramate is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Topiramate.
DapoxetineThe risk or severity of adverse effects can be increased when Topiramate is combined with Dapoxetine.
DapsoneThe metabolism of Dapsone can be decreased when combined with Topiramate.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Topiramate.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Topiramate.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Topiramate.
DesipramineThe risk or severity of adverse effects can be increased when Topiramate is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Topiramate.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Topiramate.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Topiramate is combined with Dexbrompheniramine.
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Topiramate.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Topiramate.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Topiramate.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Topiramate.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Topiramate.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Topiramate.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Topiramate.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Topiramate.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Topiramate.
DifenoxinThe risk or severity of adverse effects can be increased when Topiramate is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Topiramate.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Topiramate.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Topiramate.
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Topiramate.
DimenhydrinateThe risk or severity of adverse effects can be increased when Topiramate is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Topiramate.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Topiramate.
DopamineThe metabolism of Dopamine can be decreased when combined with Topiramate.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Topiramate.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Topiramate.
DoxepinThe risk or severity of adverse effects can be increased when Topiramate is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Topiramate.
DoxylamineThe risk or severity of adverse effects can be increased when Topiramate is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Topiramate.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Topiramate.
DronabinolThe metabolism of Dronabinol can be decreased when combined with Topiramate.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Topiramate.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Topiramate.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Topiramate.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Topiramate.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Topiramate.
EfavirenzThe risk or severity of adverse effects can be increased when Topiramate is combined with Efavirenz.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Topiramate.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Topiramate.
EnfuvirtideThe metabolism of Enfuvirtide can be decreased when combined with Topiramate.
EntacaponeThe risk or severity of adverse effects can be increased when Topiramate is combined with Entacapone.
EscitalopramThe risk or severity of adverse effects can be increased when Topiramate is combined with Escitalopram.
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Topiramate.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Topiramate.
EstradiolThe metabolism of Estradiol can be decreased when combined with Topiramate.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Topiramate.
Etacrynic acidEtacrynic acid may increase the hypokalemic activities of Topiramate.
EthanolTopiramate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Topiramate.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Topiramate.
EthosuximideThe risk or severity of adverse effects can be increased when Topiramate is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Topiramate is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Topiramate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Topiramate.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Topiramate.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Topiramate.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Topiramate.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Topiramate.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Topiramate.
EtoperidoneThe risk or severity of adverse effects can be increased when Topiramate is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Topiramate.
EtravirineThe metabolism of Etravirine can be decreased when combined with Topiramate.
EzogabineThe risk or severity of adverse effects can be increased when Topiramate is combined with Ezogabine.
FamotidineThe metabolism of Famotidine can be decreased when combined with Topiramate.
FelbamateThe risk or severity of adverse effects can be increased when Topiramate is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Topiramate.
FenfluramineThe risk or severity of adverse effects can be increased when Topiramate is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Topiramate.
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Topiramate.
FexofenadineThe risk or severity of adverse effects can be increased when Topiramate is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Topiramate is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Topiramate.
FlunarizineThe risk or severity of adverse effects can be increased when Topiramate is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Topiramate.
FluoxetineThe risk or severity of adverse effects can be increased when Topiramate is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Topiramate.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Topiramate.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Topiramate.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Topiramate.
FlutamideThe metabolism of Flutamide can be decreased when combined with Topiramate.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Topiramate is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Topiramate is combined with Fluvoxamine.
FormoterolThe metabolism of Formoterol can be decreased when combined with Topiramate.
FosphenytoinThe serum concentration of Topiramate can be decreased when it is combined with Fosphenytoin.
FosphenytoinThe risk or severity of adverse effects can be increased when Topiramate is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Topiramate.
FurosemideFurosemide may increase the hypokalemic activities of Topiramate.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Topiramate.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Topiramate is combined with gabapentin enacarbil.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Topiramate.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Topiramate.
GliclazideThe metabolism of Gliclazide can be decreased when combined with Topiramate.
GlucosamineThe metabolism of Glucosamine can be decreased when combined with Topiramate.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Topiramate.
GlyburideThe metabolism of Glyburide can be decreased when combined with Topiramate.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Topiramate.
GuanfacineThe risk or severity of adverse effects can be increased when Topiramate is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Topiramate.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Topiramate.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Topiramate.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Topiramate.
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Topiramate.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Topiramate.
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Topiramate.
HydrochlorothiazideHydrochlorothiazide may increase the hypokalemic activities of Topiramate.
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Topiramate.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Topiramate.
HydroflumethiazideHydroflumethiazide may increase the hypokalemic activities of Topiramate.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Topiramate.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Topiramate.
HydroxyzineThe risk or severity of adverse effects can be increased when Topiramate is combined with Hydroxyzine.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Topiramate.
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Topiramate.
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Topiramate.
IloperidoneThe risk or severity of adverse effects can be increased when Topiramate is combined with Iloperidone.
ImatinibThe metabolism of Imatinib can be decreased when combined with Topiramate.
ImipramineThe risk or severity of adverse effects can be increased when Topiramate is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Topiramate is combined with Indalpine.
IndapamideIndapamide may increase the hypokalemic activities of Topiramate.
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Topiramate.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Topiramate.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Topiramate.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Topiramate.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Topiramate.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Topiramate.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Topiramate.
LamotrigineThe risk or severity of adverse effects can be increased when Topiramate is combined with Lamotrigine.
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Topiramate.
LapatinibThe metabolism of Lapatinib can be decreased when combined with Topiramate.
LevetiracetamThe risk or severity of adverse effects can be increased when Topiramate is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Topiramate.
LevocabastineThe risk or severity of adverse effects can be increased when Topiramate is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Topiramate is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Topiramate is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Topiramate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Topiramate is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Topiramate.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Topiramate.
LithiumThe serum concentration of Lithium can be increased when it is combined with Topiramate.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Topiramate.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Topiramate.
LoratadineThe risk or severity of adverse effects can be increased when Topiramate is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Topiramate.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Topiramate.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Topiramate.
Lu AA21004The risk or severity of adverse effects can be increased when Topiramate is combined with Lu AA21004.
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Topiramate.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Topiramate.
MacitentanThe metabolism of Macitentan can be decreased when combined with Topiramate.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Topiramate.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Topiramate is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Topiramate is combined with Maprotiline.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Topiramate.
MeclizineThe risk or severity of adverse effects can be increased when Topiramate is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Topiramate.
MefloquineThe therapeutic efficacy of Topiramate can be decreased when used in combination with Mefloquine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Topiramate.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Topiramate.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Topiramate.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Topiramate.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Topiramate.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Topiramate.
MetaxaloneThe risk or severity of adverse effects can be increased when Topiramate is combined with Metaxalone.
MetforminThe risk or severity of adverse effects can be increased when Topiramate is combined with Metformin.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Topiramate.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Topiramate.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Topiramate.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Topiramate.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Topiramate.
MethocarbamolThe risk or severity of adverse effects can be increased when Topiramate is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Topiramate.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Topiramate.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Topiramate.
MethsuximideThe risk or severity of adverse effects can be increased when Topiramate is combined with Methsuximide.
MethyclothiazideMethyclothiazide may increase the hypokalemic activities of Topiramate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Topiramate.
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Topiramate.
MetolazoneMetolazone may increase the hypokalemic activities of Topiramate.
MetoprololThe metabolism of Metoprolol can be decreased when combined with Topiramate.
MetyrosineTopiramate may increase the sedative activities of Metyrosine.
MianserinThe therapeutic efficacy of Topiramate can be decreased when used in combination with Mianserin.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Topiramate.
MilnacipranThe risk or severity of adverse effects can be increased when Topiramate is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Topiramate.
MirtazapineTopiramate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Topiramate.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Topiramate.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Topiramate.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Topiramate.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Topiramate.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Topiramate.
NabiloneThe risk or severity of adverse effects can be increased when Topiramate is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Topiramate.
NelfinavirThe metabolism of Nelfinavir can be decreased when combined with Topiramate.
NicotineThe metabolism of Nicotine can be decreased when combined with Topiramate.
NilutamideThe metabolism of Nilutamide can be decreased when combined with Topiramate.
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Topiramate.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Topiramate.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Topiramate.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Topiramate.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Topiramate.
NortriptylineThe risk or severity of adverse effects can be increased when Topiramate is combined with Nortriptyline.
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Topiramate.
OlanzapineThe risk or severity of adverse effects can be increased when Topiramate is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Topiramate is combined with Olopatadine.
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Topiramate.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Topiramate.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Topiramate.
OrlistatThe serum concentration of Topiramate can be decreased when it is combined with Orlistat.
OrphenadrineTopiramate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Topiramate.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Topiramate.
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Topiramate.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Topiramate.
OxiconazoleThe metabolism of Oxiconazole can be decreased when combined with Topiramate.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Topiramate.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Topiramate.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Topiramate.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Topiramate.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Topiramate.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Topiramate.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Topiramate.
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Topiramate.
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Topiramate.
ParaldehydeTopiramate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Topiramate.
ParoxetineThe risk or severity of adverse effects can be increased when Topiramate is combined with Paroxetine.
PentamidineThe metabolism of Pentamidine can be decreased when combined with Topiramate.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Topiramate.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Topiramate.
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Topiramate.
PerampanelThe risk or severity of adverse effects can be increased when Topiramate is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Topiramate.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Topiramate.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Topiramate.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Topiramate.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Topiramate.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Topiramate.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Topiramate.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Topiramate.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Topiramate.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Topiramate.
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Topiramate.
PipotiazineThe risk or severity of adverse effects can be increased when Topiramate is combined with Pipotiazine.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Topiramate.
PiretanidePiretanide may increase the hypokalemic activities of Topiramate.
PizotifenThe risk or severity of adverse effects can be increased when Topiramate is combined with Pizotifen.
PodofiloxThe metabolism of Podofilox can be decreased when combined with Topiramate.
PolythiazidePolythiazide may increase the hypokalemic activities of Topiramate.
PomalidomideThe risk or severity of adverse effects can be increased when Topiramate is combined with Pomalidomide.
PramipexoleTopiramate may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Topiramate.
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Topiramate.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Topiramate.
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Topiramate.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Topiramate.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Topiramate.
PrimidoneThe risk or severity of adverse effects can be increased when Topiramate is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Topiramate.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Topiramate.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Topiramate.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Topiramate.
ProguanilThe metabolism of Proguanil can be decreased when combined with Topiramate.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Topiramate.
PromethazineThe risk or severity of adverse effects can be increased when Topiramate is combined with Promethazine.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Topiramate.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Topiramate.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Topiramate.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Topiramate.
PropranololThe metabolism of Propranolol can be decreased when combined with Topiramate.
ProtriptylineThe risk or severity of adverse effects can be increased when Topiramate is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Topiramate.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Topiramate.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Topiramate.
QuinethazoneQuinethazone may increase the hypokalemic activities of Topiramate.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Topiramate.
QuinineThe metabolism of Quinine can be decreased when combined with Topiramate.
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Topiramate.
RamelteonThe risk or severity of adverse effects can be increased when Topiramate is combined with Ramelteon.
RanitidineThe metabolism of Ranitidine can be decreased when combined with Topiramate.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Topiramate.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Topiramate.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Topiramate.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Topiramate.
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Topiramate.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Topiramate.
RopiniroleTopiramate may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Topiramate.
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Topiramate.
RotigotineTopiramate may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Topiramate.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Topiramate.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Topiramate.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Topiramate.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Topiramate.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Topiramate.
SelegilineThe metabolism of Selegiline can be decreased when combined with Topiramate.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Topiramate.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Topiramate.
SertralineThe risk or severity of adverse effects can be increased when Topiramate is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Topiramate.
SildenafilThe metabolism of Sildenafil can be decreased when combined with Topiramate.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Topiramate.
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Topiramate.
StiripentolThe risk or severity of adverse effects can be increased when Topiramate is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Topiramate.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Topiramate.
SuvorexantThe risk or severity of adverse effects can be increased when Topiramate is combined with Suvorexant.
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Topiramate.
TapentadolThe risk or severity of adverse effects can be increased when Topiramate is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Topiramate is combined with Tasimelteon.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Topiramate.
TeniposideThe metabolism of Teniposide can be decreased when combined with Topiramate.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Topiramate.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Topiramate.
TetrabenazineThe risk or severity of adverse effects can be increased when Topiramate is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Topiramate.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Topiramate.
ThalidomideTopiramate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Topiramate.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Topiramate.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Topiramate.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Topiramate.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Topiramate.
TiagabineThe risk or severity of adverse effects can be increased when Topiramate is combined with Tiagabine.
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Topiramate.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Topiramate.
TimololThe metabolism of Timolol can be decreased when combined with Topiramate.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Topiramate.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Topiramate.
TizanidineThe risk or severity of adverse effects can be increased when Topiramate is combined with Tizanidine.
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Topiramate.
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Topiramate.
TolcaponeThe risk or severity of adverse effects can be increased when Topiramate is combined with Tolcapone.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Topiramate.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Topiramate.
TorasemideTorasemide may increase the hypokalemic activities of Topiramate.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Topiramate.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Topiramate.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Topiramate.
TrazodoneThe risk or severity of adverse effects can be increased when Topiramate is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Topiramate.
TrichlormethiazideTrichlormethiazide may increase the hypokalemic activities of Topiramate.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Topiramate.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Topiramate.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Topiramate.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Topiramate.
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Topiramate.
TrimipramineThe risk or severity of adverse effects can be increased when Topiramate is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Topiramate is combined with Triprolidine.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Topiramate.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Topiramate.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Topiramate.
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Topiramate.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Topiramate.
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Topiramate.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Topiramate.
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Topiramate.
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Topiramate.
VerapamilThe metabolism of Verapamil can be decreased when combined with Topiramate.
VigabatrinThe risk or severity of adverse effects can be increased when Topiramate is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Topiramate is combined with Vilazodone.
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Topiramate.
VortioxetineThe risk or severity of adverse effects can be increased when Topiramate is combined with Vortioxetine.
WarfarinThe metabolism of Warfarin can be decreased when combined with Topiramate.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Topiramate.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Topiramate.
ZiconotideThe risk or severity of adverse effects can be increased when Topiramate is combined with Ziconotide.
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Topiramate.
ZimelidineThe risk or severity of adverse effects can be increased when Topiramate is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Topiramate.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Topiramate.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Topiramate.
ZonisamideThe risk or severity of adverse effects can be increased when Topiramate is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Topiramate.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Topiramate.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Topiramate.
Food Interactions
  • Following a single dose of the extended-release formulation with a high fat meal, Cmax of topiramate increased by 37% and shortened the Tmax to approximately 8 hours. AUC was not effected. According to the FDA label, Trokendi XR can be taken without regard to food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Nowakowska E, Kus K, Czubak A, Jedrzejewska J: Memory improving and antidepressant effects of topiramate in rats. Arzneimittelforschung. 2009;59(10):487-92. doi: 10.1055/s-0031-1296431. [PubMed:19998575 ]
  4. Braga MF, Aroniadou-Anderjaska V, Li H, Rogawski MA: Topiramate reduces excitability in the basolateral amygdala by selectively inhibiting GluK1 (GluR5) kainate receptors on interneurons and positively modulating GABAA receptors on principal neurons. J Pharmacol Exp Ther. 2009 Aug;330(2):558-66. doi: 10.1124/jpet.109.153908. Epub 2009 May 5. [PubMed:19417176 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity
Specific Function:
Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient.
Gene Name:
SCN1A
Uniprot ID:
P35498
Molecular Weight:
228969.49 Da
References
  1. Coppola G, Capovilla G, Montagnini A, Romeo A, Spano M, Tortorella G, Veggiotti P, Viri M, Pascotto A: Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial. Epilepsy Res. 2002 Mar;49(1):45-8. [PubMed:11948006 ]
  2. Ceulemans B, Cras P: "Severe myoclonic epilepsy in infancy". Relevance for the clinician of severe epilepsy starting in infancy. Acta Neurol Belg. 2004 Sep;104(3):95-9. [PubMed:15508261 ]
  3. Ceulemans B, Boel M, Claes L, Dom L, Willekens H, Thiry P, Lagae L: Severe myoclonic epilepsy in infancy: toward an optimal treatment. J Child Neurol. 2004 Jul;19(7):516-21. [PubMed:15526956 ]
  4. Korff C, Laux L, Kelley K, Goldstein J, Koh S, Nordli D Jr: Dravet syndrome (severe myoclonic epilepsy in infancy): a retrospective study of 16 patients. J Child Neurol. 2007 Feb;22(2):185-94. [PubMed:17621480 ]
  5. Nieto Barrera M, Candau Fernandez Mensaque R, Nieto Jimenez M: [Severe myoclonic epilepsy in infancy (Dravet's syndrome). Its nosological characteristics and therapeutic aspects]. Rev Neurol. 2003 Jul 1-15;37(1):64-8. [PubMed:12861512 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Voltage-gated cation channel activity
Specific Function:
Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inacti...
Gene Name:
GRIK1
Uniprot ID:
P39086
Molecular Weight:
103979.665 Da
References
  1. Rogawski MA, Gryder D, Castaneda D, Yonekawa W, Banks MK, Lia H: GluR5 kainate receptors, seizures, and the amygdala. Ann N Y Acad Sci. 2003 Apr;985:150-62. [PubMed:12724156 ]
  2. Gryder DS, Rogawski MA: Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J Neurosci. 2003 Aug 6;23(18):7069-74. [PubMed:12904467 ]
  3. Kaminski RM, Banerjee M, Rogawski MA: Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology. 2004 Jun;46(8):1097-104. [PubMed:15111016 ]
  4. Braga MF, Aroniadou-Anderjaska V, Li H, Rogawski MA: Topiramate reduces excitability in the basolateral amygdala by selectively inhibiting GluK1 (GluR5) kainate receptors on interneurons and positively modulating GABAA receptors on principal neurons. J Pharmacol Exp Ther. 2009 Aug;330(2):558-66. doi: 10.1124/jpet.109.153908. Epub 2009 May 5. [PubMed:19417176 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion into the anterior chamber of the eye. Contributes to intracellular pH regulation in the duodenal upper villous epithelium during proton-coupled peptide absorption. Stimulates the chloride-bicarbonate ex...
Gene Name:
CA2
Uniprot ID:
P00918
Molecular Weight:
29245.895 Da
References
  1. Maryanoff BE, McComsey DF, Costanzo MJ, Hochman C, Smith-Swintosky V, Shank RP: Comparison of sulfamate and sulfamide groups for the inhibition of carbonic anhydrase-II by using topiramate as a structural platform. J Med Chem. 2005 Mar 24;48(6):1941-7. [PubMed:15771438 ]
  2. Ma L, Huang YG, Deng YC, Tian JY, Rao ZR, Che HL, Zhang HF, Zhao G: Topiramate reduced sweat secretion and aquaporin-5 expression in sweat glands of mice. Life Sci. 2007 Jun 6;80(26):2461-8. Epub 2007 Apr 29. [PubMed:17521680 ]
  3. Di Fiore A, Scozzafava A, Winum JY, Montero JL, Pedone C, Supuran CT, De Simone G: Carbonic anhydrase inhibitors: binding of an antiglaucoma glycosyl-sulfanilamide derivative to human isoform II and its consequences for the drug design of enzyme inhibitors incorporating sugar moieties. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1726-31. Epub 2007 Jan 8. [PubMed:17251017 ]
  4. Casini A, Antel J, Abbate F, Scozzafava A, David S, Waldeck H, Schafer S, Supuran CT: Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. Bioorg Med Chem Lett. 2003 Mar 10;13(5):841-5. [PubMed:12617904 ]
  5. Winum JY, Scozzafava A, Montero JL, Supuran CT: Sulfamates and their therapeutic potential. Med Res Rev. 2005 Mar;25(2):186-228. [PubMed:15478125 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. May stimulate the sodium/bicarbonate transporter activity of SLC4A4 that acts in pH homeostasis. It is essential for acid overload removal from the retina and retina epithelium, and acid release in the choriocapillaris in the choroid.
Gene Name:
CA4
Uniprot ID:
P22748
Molecular Weight:
35032.075 Da
References
  1. Abbate F, Casini A, Owa T, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg Med Chem Lett. 2004 Jan 5;14(1):217-23. [PubMed:14684331 ]
  2. Dodgson SJ, Shank RP, Maryanoff BE: Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia. 2000;41 Suppl 1:S35-9. [PubMed:10768298 ]
  3. Masereel B, Rolin S, Abbate F, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties. J Med Chem. 2002 Jan 17;45(2):312-20. [PubMed:11784136 ]
  4. Vullo D, Franchi M, Gallori E, Antel J, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides. J Med Chem. 2004 Feb 26;47(5):1272-9. [PubMed:14971907 ]
Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. ChEMBL Compound Report Card [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on October 01, 2016 03:35